Key result
Elevated hsCRP levels were associated with an increased risk of CVD/CKD and MACE in East Asian populations across the majority of reviewed studies.
Why the study?
Systemic inflammation marked by hsCRP influences CVD and CKD progression, but its prognostic value in East Asian populations remains unclear.
Does elevated hsCRP predict the incidence of CVD/CKD and MACE in the East Asian population?
Does elevated hsCRP predict the incidence of CVD/CKD and MACE in the East Asian population?
Elevated hsCRP levels are consistently associated with increased risk of CVD/CKD incidence and MACE in East Asian populations, though cutoff values remain heterogeneous.
Supports hsCRP for risk stratification in East Asian CVD, HF, and CKD; confirms prognostic association in this population.
BACKGROUND: Systemic inflammation marked by high-sensitivity C-reactive protein (hsCRP) significantly influences cardiovascular disease (CVD) and chronic kidney disease (CKD) progression, yet its prognostic value in the East Asian population remains unclear. OBJECTIVES: This scoping review evaluates the prognostic value of hsCRP for CVD and CKD within these populations. METHODS: We conducted electronic searches in PubMed, Embase, and the Cochrane Library. English studies published before January 9, 2024, related to hsCRP and CVD/CKD in East Asian population were included (Protocol pre-registration number: INPLASY202490133). RESULTS: A total of 117 studies compared hsCRP levels between CVD/CKD patients and population without CVD/CKD; 30 studies explored the relationship between hsCRP level and CVD/CKD incident, and 125 studies focused on the association between hsCRP level and major adverse cardiac events (MACE) in CVD/CKD patients. Overall, 92.7% (n = 102 of 110) of studies indicated that hsCRP levels in CVD patients were significantly higher than those in population without CVD, with all studies on CKD patients reporting elevated hsCRP levels. Additionally, 75% (n = 21 of 28) of studies found an association between elevated hsCRP level and increased risk of CVD, as did both studies focusing on CKD. Regarding prognosis, 73.3% (n = 77 of 105) of studies linked higher hsCRP to MACE in atherosclerotic CVD patients, 68.8% (n = 11 of 16) in heart failure patients, and 62.5% (n = 5 of 8) in CKD patients. Notably, hsCRP cutoff values were highly heterogeneous, but mainly ranged from 1 to 3 mg/L. CONCLUSIONS: Our findings suggest that elevated hsCRP levels are associated with increased risk of CVD/CKD and MACE. Well-designed, large-scale prospective studies and subsequent meta-analyses are warranted to further validate these associations.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2025) conducted a review in Cardiovascular disease (CVD) and chronic kidney disease (CKD). Elevated hsCRP levels vs. Lower hsCRP levels or population without CVD/CKD was evaluated on CVD/CKD incidence and major adverse cardiac events (MACE). Elevated hsCRP levels were associated with an increased risk of CVD/CKD and MACE in East Asian populations across the majority of reviewed studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: